Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, et al. Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv79–95.

Article  PubMed  CAS  Google Scholar 

Redondo A, Bagué S, Bernabeu D, Ortiz-Cruz E, Valverde C, Alvarez R, et al. Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). Cancer Chemother Pharmacol. 2017;80(6):1113–31.

Article  PubMed  PubMed Central  Google Scholar 

Board WCoTE. Soft tissue and Bone Tumours. WHO Classification of Tumours tE; 2020.

Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23(9):2004–11.

Article  PubMed  CAS  Google Scholar 

Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival–a report from the children’s Oncology Group. J Clin Oncol. 2008;26(4):633–8.

Article  PubMed  CAS  Google Scholar 

Pignochino Y, Dell’Aglio C, Inghilleri S, Zorzetto M, Basiricò M, Capozzi F, et al. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. BMC Cancer. 2015;15:374.

Article  PubMed  PubMed Central  Google Scholar 

Chiabotto G, Grignani G, Todorovic M, Martin V, Centomo ML, Prola E et al. Pazopanib and Trametinib as a synergistic strategy against Osteosarcoma: preclinical activity and molecular insights. Cancers (Basel). 2020;12(6).

Fioramonti M, Fausti V, Pantano F, Iuliani M, Ribelli G, Lotti F, et al. Cabozantinib affects Osteosarcoma Growth through a direct effect on Tumor cells and modifications in bone microenvironment. Sci Rep. 2018;8(1):4177.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Grignani G, Palmerini E, Ferraresi V, D’Ambrosio L, Bertulli R, Asaftei SD, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16(1):98–107.

Article  PubMed  CAS  Google Scholar 

Pignochino Y, Dell’Aglio C, Basiricò M, Capozzi F, Soster M, Marchiò S, et al. The combination of Sorafenib and Everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res. 2013;19(8):2117–31.

Article  PubMed  CAS  Google Scholar 

Grignani G, Palmerini E, Dileo P, Asaftei SD, D’Ambrosio L, Pignochino Y, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23(2):508–16.

Article  PubMed  CAS  Google Scholar 

Pignochino Y, Grignani G, Cavalloni G, Motta M, Tapparo M, Bruno S, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer. 2009;8:118.

Article  PubMed  PubMed Central  Google Scholar 

Giordano G, Merlini A, Ferrero G, Mesiano G, Fiorino E, Brusco S et al. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing’s Sarcoma and Chondrosarcoma. Cells. 2021;10(11).

Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, et al. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell. 2012;22(6):765–80.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fan J, Wei Q, Koay EJ, Liu Y, Ning B, Bernard PW, et al. Chemoresistance Transmission via exosome-mediated EphA2 transfer in pancreatic Cancer. Theranostics. 2018;8(21):5986–94.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Garcia-Monclús S, López-Alemany R, Almacellas-Rabaiget O, Herrero-Martín D, Huertas-Martinez J, Lagares-Tena L, et al. EphA2 receptor is a key player in the metastatic onset of ewing sarcoma. Int J Cancer. 2018;143(5):1188–201.

Article  PubMed  PubMed Central  Google Scholar 

Xiao T, Xiao Y, Wang W, Tang YY, Xiao Z, Su M. Targeting EphA2 in cancer. J Hematol Oncol. 2020;13(1):114.

Article  PubMed  PubMed Central  Google Scholar 

Limited B. Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression [ https://clinicaltrials.gov/study/NCT04180371?term=epha2&rank=5&tab=table

Hospital CPG. Combination of CAR-DC Vaccine and ICIs in Malignant Tumors [ https://clinicaltrials.gov/study/NCT05631886?term=epha2&rank=3

Center MDAC. EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors [ https://clinicaltrials.gov/study/NCT01591356?term=epha2&rank=1

Wilson K, Shiuan E, Brantley-Sieders DM. Oncogenic functions and therapeutic targeting of EphA2 in cancer. Oncogene. 2021;40(14):2483–95.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kania A, Klein R. Mechanisms of ephrin-eph signalling in development, physiology and disease. Nat Rev Mol Cell Biol. 2016;17(4):240–56.

Article  PubMed  CAS  Google Scholar 

Atlas THP. Eph receptors [ https://www.proteinatlas.org/search/eph+receptors

Lisabeth EM, Falivelli G, Pasquale EB. Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol. 2013;5(9).

Liang LY, Patel O, Janes PW, Murphy JM, Lucet IS. Eph receptor signalling: from catalytic to non-catalytic functions. Oncogene. 2019;38(39):6567–84.

Article  PubMed  CAS  Google Scholar 

Pasquale EB. Eph-ephrin promiscuity is now crystal clear. Nat Neurosci. 2004;7(5):417–8.

Article  PubMed  CAS  Google Scholar 

Murai KK, Pasquale EB. Eph’ective signaling: forward, reverse and crosstalk. J Cell Sci. 2003;116(Pt 14):2823–32.

Article  PubMed  CAS  Google Scholar 

Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010;10(3):165–80.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pasquale EB. Eph receptors and ephrins in cancer progression. Nat Rev Cancer. 2024;24(1):5–27.

Article  PubMed  CAS  Google Scholar 

Gatto G, Morales D, Kania A, Klein R. EphA4 receptor shedding regulates spinal motor axon guidance. Curr Biol. 2014;24(20):2355–65.

Article  PubMed  CAS  Google Scholar 

Janes PW, Wimmer-Kleikamp SH, Frangakis AS, Treble K, Griesshaber B, Sabet O, et al. Cytoplasmic relaxation of active eph controls ephrin shedding by ADAM10. PLoS Biol. 2009;7(10):e1000215.

Article  PubMed  PubMed Central  Google Scholar 

Barquilla A, Pasquale EB. Eph receptors and ephrins: therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2015;55:465–87.

Article  PubMed  CAS  Google Scholar 

Ieguchi K, Tomita T, Omori T, Komatsu A, Deguchi A, Masuda J, et al. ADAM12-cleaved ephrin-A1 contributes to lung metastasis. Oncogene. 2014;33(17):2179–90.

Article  PubMed  CAS  Google Scholar 

Alford SC, Bazowski J, Lorimer H, Elowe S, Howard PL. Tissue transglutaminase clusters soluble A-type ephrins into functionally active high molecular weight oligomers. Exp Cell Res. 2007;313(20):4170–9.

Article  PubMed  CAS  Google Scholar 

Lagares D, Ghassemi-Kakroodi P, Tremblay C, Santos A, Probst CK, Franklin A, et al. ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis. Nat Med. 2017;23(12):1405–15.

Article  PubMed  PubMed Central  CAS  Google Scholar